{"id":4651,"date":"2025-03-31T18:12:15","date_gmt":"2025-03-31T18:12:15","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ranitidine-txt\/"},"modified":"2025-03-31T18:12:15","modified_gmt":"2025-03-31T18:12:15","slug":"ranitidine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ranitidine-txt\/","title":{"rendered":"ranitidine.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nH2 antagonist:Conditions associated with hyperacidity

DOSE IN NORMAL RENAL FUNCTION <\/H3>Oral: 150\u2013300 mg once or twice daily Zollinger Ellison: 150 mg 3 times daily up to 6 g\/dayIM\/Slow IV injection: 50 mg every 6\u20138 hours

IV infusion <\/H4>: 25 mg\/hour for 2 hours, 6\u20138 hourly; or for stress ulceration prophylaxis 125\u2013250 mcg\/kg\/hour

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :314.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :15<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Oral: 30\u201335; IV: 80<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.4<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20133\/6\u20139

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50\u2013100% of normal dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Probably dialysed. 50 mg every 8\u201312 hours.1 Oral: dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAlpha-blockers: effects of tolazoline antagonised\n
  • Antifungals: absorption of itraconazole and ketoconazole reduced\n
  • Ciclosporin: may increase or not change ciclosporin levels; nephrotoxicity, additive hepatotoxicity and thrombocytopenia reported

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV peripherally, IM (undiluted)

    Rate of Administration <\/H4>Bolus: 50 mg made up to 20 mL, over at least 2 minutesIntermittent infusion: 50 mg to 100 mL of appropriate intravenous solution run over 2 hours
    Continuous infusion: required dose in 250 mL of intravenous fluid over 24 hours

    Comments<\/H4>Compatible with sodium chloride 0.9%, glucose 5% and other fluids. Admixtures stable for 24 hours
    Minimum volume: can be used undiluted as a bolus over at least 2 minutes.

    OTHER INFORMATION <\/H4>In CKD 5 usually twice daily for IV preparation and normal dose for oral
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE H2 antagonist:Conditions associated with hyperacidity DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4651","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4651"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4651\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}